Source: In Vitro Diagnostics Observer, Biotest Biotech

Recently,Biotest Biotech and Zhongke Imagery (Nanjing) Technology Co., Ltd. Signed a Strategic Cooperation Framework Agreement in Hangzhou, with Both Parties to Engage in In-Depth Collaboration in the Joint Development of Brain-Computer Interface and In Vitro Diagnostic Reagents, Medical Device Registration and Market Access Support, and Clinical Application and Promotion of the Brain-Computer Interface Industry Chain

Biotest Biotech stated that this collaboration marks the company’s expansion of its industrial layout into the upstream supply chain of brain-computer interfaces (BCIs) and the field of embodied intelligent interaction. Previously, Biotest Biotech had led the latest round of financing for Zhongke Imagery through the Biotest BCI Fund, taken equity stakes in multiple BCI enterprises, and established a special industrial fund worth RMB 200 million.

The collaboration between the two parties focuses on deep synergy in industrial capital, integrated innovation in IVD and BCI, and breakthroughs in commercialization pain points. The core breakthrough lies in the joint development of postoperative immune response testing reagents and blood biomarker monitoring solutions, exploring non-invasive assessment for early screening of implant infections, biocompatibility, and performance degradation trends, thereby filling the long-standing gap in industry safety monitoring.

Biotest Biotech will leverage its regulatory compliance expertise in medical devices and global sales network to provide Zhongke Imagery with registration and filing support for NMPA, FDA, and CE certifications, thereby accelerating the international market entry of its products. The two parties will also jointly establish a “R&D–Clinical–Feedback” data closed-loop system, prioritize procurement collaboration in downstream application scenarios such as mental health, and deepen their synergy in the fields of implant-associated infection screening and attenuation early warning.

Zhongke Imagery is a brain-computer interface (BCI) technology enterprise incubated by the Institute of Automation, Chinese Academy of Sciences. It focuses on the deep integration of "brain-computer AI embodiment," achieving full-chain automation from "brain intent decoding" to "AI autonomous planning" and "robotic arm embodied execution." In routine animal experiments conducted in April 2025, Zhongke Imagery decoded the motor intent of macaques in just 0.2 seconds, with AI autonomously completing motion planning and grasp execution for the robotic arm and dexterous hand.

Furthermore, Zhongke Imagery has proposed the Brain-Computer Interface Grading System (BCIG) and is advancing human clinical trials for Level 3 BCIG brain-computer interfaces.

May 2025,Biotest Biotech Strategically Invests in Hangzhou Qingshi Yongjun Medical Equipment Co., Ltd., Holding a 5% Stake Post-InvestmentThe company’s core founding team hails from the State Key Laboratory of Brain-Machine Intelligence at Zhejiang University, making it the first research team in China to achieve therapeutic outcomes for treatment-resistant severe depression through precise targeting via implantable deep brain stimulation.

January 2026,Biotest Biotech Strategically Invests in Hangzhou Haoshi Tianhui Technology Co., Ltd., Holding a 16% Stake Post-Investment.The company conducts diagnostics and adjunctive therapy using non-invasive brain-computer interfaces (BCIs). Its independently developed medical-grade non-invasive BCI and mental health assessment devices can complete precise quantitative assessments of emotional disorders, such as depression and anxiety, in as little as 90 seconds.

In March 2026, Biotest Biotech established a special industrial fund for brain-computer interfaces and brain science, with a total scale of RMB 200 million, primarily aimed at investing in unlisted companies within the domestic and international brain-computer interface and brain science-related industrial chains.Among them, Biotest Biotech, as a limited partner, subscribed to RMB 190 million, accounting for 95%. Biotest Biotech stated that the company will leverage the expertise and resource advantages of professional investment institutions to accelerate the strategic layout in brain-computer interfaces and promote the integration and sharing of advantageous resources.